Related Articles
Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo